ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,408.90
0.36%
S&P ASX All Technology
3,893.00
0.20%
Brent Oil
77.405
0.29%
US Dollar vs AUD
1.58914
0.35%
Bitcoin
99,453.81
-4.98%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. KalVista Pharmaceuticals Inc (KALV) Share Price

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc (KALV)

NASDAQ
8.61
0.05
(0.58%)
Closed 25 January 8:00AM
Delayed by 15 minutes
8.61
0.00
( 0.00% )
Pre Market: 8:00PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.61
Bid
7.41
Offer
14.00
Volume
-
0.00 Day's Range 0.00
7.30 52 Week Range 16.88
Market Cap
425.489M
Previous Close
8.61
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
393,008
Shares Outstanding
49,417,986
Dividend Yield
-
PE Ratio
-3.36
Earnings Per Share (EPS)
-2.56
Revenue
-
Net Profit
-126.64M

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angio... KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kalvista.com
Headquarters
Dover, Delaware, USA
Founded
-
KalVista Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KALV. The last closing price for KalVista Pharmaceuticals was US$8.61. Over the last year, KalVista Pharmaceuticals shares have traded in a share price range of US$ 7.30 to US$ 16.88.

KalVista Pharmaceuticals currently has 49,417,986 shares in issue. The market capitalisation of KalVista Pharmaceuticals is US$425.49 million. KalVista Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.36.

Ask ADVFN Intelligence (AI)

KALV Latest News

More News

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

–Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan– – Submission advances Company’s strategic plan to address unmet needs...

21 January 2025
Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans

17 January 2025
Edgar (US Regulatory)

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an...

08 January 2025
Business Wire

Form 8-K - Current report

16 December 2024
Edgar (US Regulatory)

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a...

16 December 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

10 December 2024
Edgar (US Regulatory)

Form 8-K - Current report

06 December 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 December 2024
Edgar (US Regulatory)

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

–Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025– –Multinational regulatory submissions for sebetralstat position Company to transform...

05 December 2024
Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase...

04 December 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.252.990430622018.368.88448.22727818.64664916CS
40.111.294117647068.59.15497.32662498.25769282CS
12-2.69-23.805309734511.312.857.33930089.35456792CS
26-6.22-41.942009440314.8314.977.335766410.5708593CS
52-4.77-35.650224215213.3816.887.346100012.2199063CS
156-3.13-26.66098807511.7417.3454.1234670510.60879215CS
260-8.07-48.38129496416.68454.1231809515.6620252CS

KALV - Frequently Asked Questions (FAQ)

What is the current KalVista Pharmaceuticals share price?
The current share price of KalVista Pharmaceuticals is US$ 8.61
How many KalVista Pharmaceuticals shares are in issue?
KalVista Pharmaceuticals has 49,417,986 shares in issue
What is the market cap of KalVista Pharmaceuticals?
The market capitalisation of KalVista Pharmaceuticals is USD 425.49M
What is the 1 year trading range for KalVista Pharmaceuticals share price?
KalVista Pharmaceuticals has traded in the range of US$ 7.30 to US$ 16.88 during the past year
What is the PE ratio of KalVista Pharmaceuticals?
The price to earnings ratio of KalVista Pharmaceuticals is -3.36
What is the reporting currency for KalVista Pharmaceuticals?
KalVista Pharmaceuticals reports financial results in USD
What is the latest annual profit for KalVista Pharmaceuticals?
The latest annual profit of KalVista Pharmaceuticals is USD -126.64M
What is the registered address of KalVista Pharmaceuticals?
The registered address for KalVista Pharmaceuticals is 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
What is the KalVista Pharmaceuticals website address?
The website address for KalVista Pharmaceuticals is www.kalvista.com
Which industry sector does KalVista Pharmaceuticals operate in?
KalVista Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AALAmerican Airlines Group Inc
US$ 16.96
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.5092
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.14
(0.00%)
0
AACGATA Creativity Global
US$ 0.84
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.96
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.5092
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.14
(0.00%)
0
AACGATA Creativity Global
US$ 0.84
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.96
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 74.5092
(0.00%)
0
AADIAadi Bioscience Inc
US$ 3.14
(0.00%)
0
AACGATA Creativity Global
US$ 0.84
(0.00%)
0

KALV Discussion

View Posts
Monksdream Monksdream 7 months ago
KALV 10Q expected July 5
👍️0
Monksdream Monksdream 10 months ago
KALV over $10
👍️0
Monksdream Monksdream 11 months ago
KALV new 52=week high
👍️0
clydesur clydesur 12 months ago
INSIDER PURCHASE / SYNDICATE

KALV - 10% OWNER Venrock Healthcare P 86,048 $14.618
👍️0
Monksdream Monksdream 12 months ago
KALV new 52 week high
👍️0
Monksdream Monksdream 1 year ago
KALV new 52 week high
👍️0
Femto99 Femto99 4 years ago
I would not even buy the shares at $20.
👍️0
Femto99 Femto99 4 years ago
All in puts!
👍️0
Stock_Barber Stock_Barber 4 years ago
Boom!

Killed it with puts today!

👍️0
ClayTrader ClayTrader 4 years ago
* * $KALV Video Chart 02-09-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Stock_Barber Stock_Barber 4 years ago
This company is a disaster...

👍️0
make it happen make it happen 4 years ago
The company is delinquent.
👍️0
make it happen make it happen 4 years ago
? lol

Profitability
Profit Margin 0.00%
Gross Profit (ttm) $-27.5M
EBITDA $-48.38M
Net Income Avi to Common (ttm) $-37.12M
Diluted EPS (ttm) -2.08

Book Value Per Share (mrq) $3.63

Going to keep diluting more and more
👍️0
make it happen make it happen 4 years ago
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.

Operating Margin (ttm) -905.50%

Management Effectiveness

Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%

Revenue  $5.4M
Revenue Per Share  $0.30

👍️0
TFMG TFMG 5 years ago


$KALV Kalvista Pharma Trend Break



Major Downtrend broken
Broken above 200ma
Volume increased
MACD reversed
RSi in bullish uptrend



👍️0
whytestocks whytestocks 6 years ago
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...

Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html
👍️0
whytestocks whytestocks 6 years ago
News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html
👍️0
stocktrademan stocktrademan 6 years ago
KALV buy 28.87



normal chart







log chart






👍️0
whytestocks whytestocks 6 years ago
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html
👍️0
countryrapper2000 countryrapper2000 7 years ago
Where is everyone?
👍️0
TheFinalCD TheFinalCD 7 years ago
$17.85 !!


KALV
👍️0
Lone Wolf Lone Wolf 7 years ago
Sniffer rocket ship today!! Wheeee.

KALV
👍️0
TheFinalCD TheFinalCD 7 years ago
$15.50 now ~ keep rollin



$KALV
👍️0
kondziu kondziu 8 years ago
http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmaceuticals-sells-raptor-pharmaceutical-cm744623
👍️0
Warchest Warchest 8 years ago
$8.25 now ~ keep rollin
👍️0
ming1234 ming1234 8 years ago
any positive news and volume will move this north
👍️0
Warchest Warchest 8 years ago
LIVE action starting !!!
👍️0
Warchest Warchest 8 years ago
watching close ~
👍️0
Toxic Avenger Toxic Avenger 8 years ago
The way this is dropping, there has to be a lawsuit over the sale of cash at 60% off.
Where are those ambulance chasing securities lawyers?
👍️0
MSparks6 MSparks6 8 years ago
So when will CBYL holders be issued KALV common stock?
👍️0
Toxic Avenger Toxic Avenger 8 years ago
CBYL is now KALV with a 1:14 reverse stock split.

Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.
👍️0
Iam_in Iam_in 8 years ago
$6.00
👍️0
Iam_in Iam_in 8 years ago
New Ticker symbol now: KALV
👍️0
Iam_in Iam_in 8 years ago
Correction : $5.49 PM
👍️0
Iam_in Iam_in 8 years ago
WOW - look at this $0,89---> $4,60

New Ticker name now : KALV

look at NASDAQ - PM
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Apparently the merger deal was approved by a huge margin.

Still don't get it.
👍️0
ClayTrader ClayTrader 8 years ago
* * $CBYL Video Chart 11-21-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 8 years ago
Attempting to break 0.72. GL to holders
👍️0
beginneer beginneer 8 years ago
We'll see how this goes. Hopefully back to over a dollar.
👍️0
Toxic Avenger Toxic Avenger 8 years ago
CBYL continuing its upward momentum pre-market.
👍️0
ClayTrader ClayTrader 8 years ago
* * $CBYL Video Chart 11-18-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 8 years ago
Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.
👍️0
Toxic Avenger Toxic Avenger 8 years ago
New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.

Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.

I can only hope!
👍️0
beginneer beginneer 8 years ago
Somethings fishy going on here. Why the sudden spike in volume? New buyer in sight?
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Fun while it lasted.
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Big bounce today. Anyone know why?
👍️0
Toxic Avenger Toxic Avenger 8 years ago
$700k / month for a company that has only a few execs and no business left???

No wonder they want to merge. If they liquidate, the execs all lose their gravy train.

Maybe that can be part of the class action suit.
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 8 years ago
Sadly, I don't think so.
👍️0

Your Recent History

NASDAQ
KALV
KalVista Pharmaceuticals
AQSE
VDEV.GB
Vanguard Ftse Developed ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads